BAILEY GIBBS: Open Payments
NPI 1033891387 · ROSEBURG, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,755 in 59 payments from 19 companies in 2025. Trend: 2023 $0 · 2024 $260 · 2025 $1,755
Food & beverage: $1,755
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $533 |
| ABBVIE INC. | 8 | $239 |
| Axsome Therapeutics, Inc. | 3 | $145 |
| Exact Sciences Corporation | 5 | $118 |
| Madrigal Pharmaceuticals | 5 | $114 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $108 |
| GlaxoSmithKline, LLC. | 3 | $92 |
| Novo Nordisk Inc | 4 | $74 |
| PFIZER INC. | 3 | $56 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $48 |
Products named: AIRSUPRA, BREZTRI, VRAYLAR, FARXIGA, Auvelity, REZDIFFRA, CAPLYTA, TRELEGY ELLIPTA.
Industry payments across OR — which companies pay providers there.
